1. Vitek ® 2 MICs as first-line phenotypic screening method for carbapenemase-producing Pseudomonas aeruginosa .
- Author
-
Sieswerda E, Bosch T, Lankelma JM, Schouls LM, and Dijk KV
- Subjects
- Bacterial Proteins, Ciprofloxacin pharmacology, Imipenem pharmacology, Tobramycin pharmacology, beta-Lactamases, Anti-Bacterial Agents pharmacology, Microbial Sensitivity Tests, Pseudomonas aeruginosa drug effects, Pseudomonas aeruginosa genetics
- Abstract
Aim: To define sensitivity and specificity of Vitek
® 2 MICs as phenotypic screening method for carbapenemase-producing Pseudomonas aeruginosa . Materials & methods: We determined Vitek® 2 MICs of antipseudomonal antimicrobials in 130 unrelated carbapenemase-producing P. aeruginosa and 129 carbapenemase-negative P. aeruginosa isolates within a Dutch carbapenemase-surveillance database. We calculated test characteristics of single and combined antimicrobial MICs for carbapenemase production. Results: Vitek® 2 MIC above epidemiological cutoff of both imipenem and tobramycin or ciprofloxacin and tobramycin displayed a sensitivity of 96.2% and specificity of 89.6% for carbapenemase production in P. aeruginosa . Conclusion: Vitek® 2 MIC> epidemiological cut-off values seem sensitive and specific as a phenotypic screening strategy for carbapenemase-producing P. aeruginosa . Combining imipenem and tobramycin or ciprofloxacin and tobramycin performed best as a screening strategy for defining which P. aeruginosa isolates should undergo confirmatory tests for carbapenemase production.- Published
- 2021
- Full Text
- View/download PDF